Lilly and Abcellera provide the first clinical data we've seen for monoclonal antibodies against the coronavirus. The good news is that it seems to work. But it's not a slam dunk by any standards, either
Good analysis of the puzzling data from Eli Lilly's #Covid19 monoclonal antibody therapy from . What does it mean when the middle dose seems better than both the low dose AND the higher dose? Dunno, but not what you'd hope for.